UPDATE: Minaris Advanced Therapies has just announced the appointment of Dr. Orla Cloak as its new Chief Executive Officer, effective immediately. This pivotal leadership change, confirmed on July 21, 2025, comes as the company aims to enhance its role in the rapidly evolving field of Cell and Gene therapies.
Dr. Cloak, a distinguished executive with over 20 years of experience in the Pharma and Life Science industries, will bring a wealth of knowledge to Minaris. Previously, she held senior leadership roles at Lonza, including her most recent position as Senior Vice President and Head of the Lonza Bioscience business. Her extensive background in innovation and strategic leadership positions her as a key player in driving Minaris’s growth.
Iain Baird, Chairman of the Board at Minaris, expressed enthusiasm about Cloak’s appointment, stating,
“On behalf of the board, I am delighted to welcome Orla to Minaris Advanced Therapies. Her leadership will be instrumental to achieving our mission of supporting customers to successfully commercialize their innovative therapies.”
In her own words, Dr. Cloak shared,
“I am honored to join Minaris Advanced Therapies at such a pivotal time. I look forward to working with the talented team here to build on the company’s strong foundations and drive its next phase of growth.”
Minaris Advanced Therapies, headquartered in Philadelphia, Pennsylvania, operates as a global contract development and manufacturing organization (CDMO) and contract testing provider focused exclusively on Cell and Gene therapies. The company boasts over 650,000 square feet of infrastructure across the United States, Europe, and Asia, and has successfully manufactured and released over 7,500 GMP batches.
This leadership transition is critical as Minaris continues to support therapy developers through early-stage development, clinical trials, and commercial manufacturing. The company’s commitment to operational excellence and sustainable growth is underscored by its recent advancements in the sector.
As Minaris Advanced Therapies welcomes Dr. Cloak, industry observers will be closely monitoring how her vision and expertise shape the future of the organization. The coming weeks will be crucial as she outlines her strategic plans to leverage the company’s robust capabilities and drive innovation within the healthcare landscape.
For ongoing updates about Minaris Advanced Therapies and Dr. Orla Cloak’s initiatives, stay tuned to credible news sources and official announcements.
